This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

A Diagnostic Test for Dementia With Lewy Bodies

Sponsored by CND Life Sciences

About this trial

Last updated 2 years ago

Study ID

101

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18-75 Years
50 to 85 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended a year ago

What is this trial about?

The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

What are the participation requirements?

Yes

Inclusion Criteria

1. Men and women 50 to 85 years of age

2. Clinical diagnosis of mild cognitive impairment, and a presumed etiology of DLB or AD at enrollment

No

Exclusion Criteria

1. Clinical evidence of severe peripheral vascular disease (Fazekas score of ≥ 3, or a large vessel stroke of ≥ 2 cm, history of ulceration, poor wound healing, vascular claudication)

2. Clinically active coronary artery or cerebrovascular disease

3. Current smoker or alcoholism

4. History of allergic reaction to local anesthesia (for biopsy collection)

5. Use of anticoagulants (aspirin or Plavix alone is allowed)

6. Significantly impaired wound healing or history of scarring or keloid formation

Locations

Location

Status

Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting